Skip to content

Surfactant Protein Genetic Variants in COVID-19 Infection

Surfactant Protein Genetic Variants in COVID-19 Infection

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04650191
Enrollment
300
Registered
2020-12-02
Start date
2020-03-01
Completion date
2022-06-30
Last updated
2022-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Infection

Brief summary

Surfactant protein plays important role in innate immunity against respiratory viral infections. However, investigators have shown that the surfactant protein polymorphisms are associated with severity of various pulmonary diseases such as respiratory syncytial virus (RSV), tuberculosis, pediatric acute lung injury. COVID-19 virus gains entry through the respiratory system and responsible for death due to acute respiratory failure. There is a considerable heterogeneity in presentation of COVID-19 infection from asymptomatic patients to severe infection requiring intensive care and some may die. Considering reports of COVID-19 related deaths/severe disease in the same family, it is possible that genetics play an important role in severity of COVID-19 infection. Investigators propose to study the association of surfactant proteins in COVID-19 patients. Key Objectives: a) Characterize genetic markers within the surfactant protein genes in COVID-19 positive patients, b) To determine if there is a correlation between certain genetic markers and the severity of COVID-19 infection which may be used as a prognostic marker, c) To correlate genetic markers with immune studies.

Interventions

DNA will be extracted from whole blood from study subjects

Sponsors

Milton S. Hershey Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Days to 90 Years
Healthy volunteers
No

Inclusion criteria

The major inclusion criteria is a confirmed diagnosis of COVID-19 infection performed on nasopharyngeal secretions by enzyme immunoassay or culture in patients.

Exclusion criteria

Patients unable to sign informed consent will be excluded.

Design outcomes

Primary

MeasureTime frame
Correlation of surfactant protein genetic variants with severity of COVID-19 infection12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 16, 2026